1 / 12

Forecasting for ARVs medicines Baseline Estimates November 2005

Forecasting for ARVs medicines Baseline Estimates November 2005. Methods. Volumes of the currently sales of ARVs were collected from AMDS partner organizations ,and grouped in 3 groups: Low Income countries Middle Income countries Brazil.

terra
Download Presentation

Forecasting for ARVs medicines Baseline Estimates November 2005

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Forecasting for ARVs medicines Baseline Estimates November 2005

  2. Methods • Volumes of the currently sales of ARVs were collected from AMDS partner organizations ,and grouped in 3 groups: • Low Income countries • Middle Income countries • Brazil

  3. Calculation of the number of patients from procurement data 1) Number of smallest pharmaceutical units procured was converted in number of patient-years of drugs used 2) Percentage of individual drugs used was expressed against the total volume of API procured (expressed in patient-years) 3) Drugs were deemed to be used as first line and second line drugs when recommended as such for the majority of patients according to the 2003 WHO ART guidelines.

  4. WHO recommendations for first and second line drugs First line ARVs NRTI stavudine (d4T), zidovudine (ZDV), lamivudine (3TC) NNRTI nevirapine (NVP), efavirenz (EFV) Second Line NRTI/NtRTI Tenofovir (TDF), abacavir (ABC), didanosine (ddI), PI lopinavir (LPV), ritonavir (r), saquinavir (SQV) , indinavir (IDV), nelfinavir (NFV), atazanavir (ATV).

  5. Volume de ARV transactions reported in GPRM between January 1,2005 and July 31,2005 (in patient-years)

  6. Volume de ARV transactions reported in GPRM between January 1,2005 and July 31,2005 (in patient-years)

  7. Volume de ARV transactions reported in GPRM between January 1, 2005 and July 31,2005(in patient-years)

  8. Volume of ARV transacted in Brazil January 1 to December 31, In 2004 patient-years

  9. Volume of ARV transacted in Brazil January 1 to December 31, In 2004 patient-years

  10. Volume of ARV transacted in Brazil January 1,2004 to December 31, 2004 (in patient-years)

  11. A glimpse of the future: Likely orientation of the 2006 WHO ART guidelines Comparison of 1st and 2nd Line ARV Drug Formularies for Adults and Adolescents (2003 vs 2006)

  12. A glimpse of the future: Likely orientation of the 2006 WHO ART guidelines Comparison of 1st and 2nd Line ARV Drug Formularies for Adults and Adolescents (2003 vs 2006) Triple NRTI alternative d4T*or ZDV EFV 3TC or FTC NVP ABC or TDF Classical NRTI/NNRTI approach

More Related